JAK2 V617F Mutation Detection for Polycythemia Vera Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Vaquez polyglobulia (Polycythemia Vera) are unreliable and lack specificity, relying on clinical criteria and erythroid colony formation assays that are cumbersome and not universally available, with no effective treatments targeting the underlying molecular anomaly.
Innovation Solution
Identification of the JAK2 V617F mutation as a diagnostic marker using LightCycler and TaqMan technologies, allowing for its detection in granulocytes, which correlates with PV diagnosis and avoids the need for erythroid colony assays and bone marrow testing, and the development of specific inhibitors and siRNA to target this mutation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If erythroid colony formation assays and bone marrow testing are used for diagnosis, then diagnostic reliability is improved, but device complexity and ease of operation deteriorate due to cumbersome procedures and lack of universal availability
Solution Approach 1:
The patent replaces complex mechanical/biological assays (erythroid colony formation, bone marrow testing) with a molecular biology-based PCR detection method. This substitution maintains diagnostic reliability by detecting the specific JAK2 V617F mutation while eliminating the need for cumbersome cell culture and invasive bone marrow procedures, making the test universally available and easier to perform.
2Measurement precision
If erythroid colony formation assays are used for diagnosis, then diagnostic precision is improved, but loss of time increases due to substantial technician-time required
Solution Approach 1:
The patent performs preliminary identification of the JAK2 V617F mutation through PCR amplification and sequencing, which provides diagnostic precision without requiring time-consuming erythroid colony formation assays. By detecting the specific molecular marker directly from DNA, the method eliminates the need for prolonged cell culture and technician intervention, significantly reducing time loss while maintaining accuracy.
3Measurement precision
If invasive bone marrow testing is performed, then measurement precision is improved, but object-affected harmful factors increase due to patient discomfort and procedural invasiveness
Solution Approach 1:
The patent extracts the essential diagnostic information (JAK2 V617F mutation status) directly from circulating blood cells without requiring invasive bone marrow sampling. By taking out the key molecular marker detection from the complex bone marrow procedure, the method maintains measurement precision while completely eliminating the harmful effects associated with invasive testing, including patient discomfort and procedural risks.
Data Source
AI summary
The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group, and to the identification of specific inhibitors and siRNA.